Joachim Gullbo, Scientific Advisor
WntResearch has once again engaged Joachim Gullbo as scientific advisor, a role he previously held but had to leave when he started a position in the United States.
Joachim Gullbo, MD, PhD, and Adjunct Professor of Clinical Pharmacology at Uppsala University, has a solid scientific background in the development and evaluation of anticancer drugs, from preclinical research to clinical trials. He is co-author of more than 85 scientific publications in the field of cancer.
Joachim Gullbo has Swedish clinical specialist training in clinical pharmacology and oncology, and was previously head of the oncology section at Uppsala University Hospital. He is currently Medical Monitor at Theradex Oncology in Princeton, USA. Joachim is one of the founders of Oncopeptides where he now remains as scientific advisor.
"I look forward to once again being able to act as scientific advisor to WntResearch and the drug candidate Foxy-5. To follow its clinical development, contribute to understanding and benefit from the ad hoc observations and be involved in developing the plan for the continued development will be very interesting", says Joachim Gullbo.
"It is extremely gratifying to once again have Joachim, with his solid expertise and experience, as scientific advisor to WntResearch", says Pernilla Sandwall.
For further information:
Pernilla Sandwall, VD
E-mail: pernilla.sandwall@wntresearch.com
About Wntresearch AB
WntResearch is a biotech company in oncology that develops new therapies intended to prevent the metastatic process. The company's research is focused on studying the endogenous protein WNT5A, which in scientific studies has shown to affect tumour cells' ability to move and spread in the body. WntResearch drug candidate Foxy-5 is a peptide that mimics the function of WNT5A and is intended to reduce the mobility and spread of cancer cells thus preventing metastases from occurring. Although current cancer treatment has become more effective, there are no effective ways to prevent the onset of metastases that cause about 90 percent of all cancer-related deaths. Foxy-5 has a unique mechanism of action and has shown a good safety profile with few side effects in two Phase I clinical trials. The safety and efficacy of Foxy-5 are now being evaluated in the ongoing Phase 2 clinical trial NeoFox, in patients with stage II-III colon cancer.
WntResearch is listed on the Spotlight Stock Market. For more information, please visit: www.wntresearch.com.
Follow WntResearch on Linked in